Ahead of the EMA’s CHMP publishing its April meeting highlights, Biogen has revealed a positive opinion for its Tofidence biosimilar tocilizumab rival to RoActemra. However, Fresenius already has a version on the market.

AstraZeneca’s CEO says his potential 11% pay rise is needed to help the European industry remain competitive with its higher paying US counterparts.

At-home fertility-related hormone test developer Proov sells equity stake to entertainers and expectant parents Ashanti and Nelly; sexual and vaginal health product firm Good Clean Love moves from its founder as leader to a consumer health industry executive.

CEO Paul Hudson says that the French major will continue to progress early-stage cancer projects despite jettisoning some oncology programs in favor of reallocating much of its research budget to immunology.